IL201690A0 - Raf inhibitors for the treatment of thyroid cancer - Google Patents
Raf inhibitors for the treatment of thyroid cancerInfo
- Publication number
- IL201690A0 IL201690A0 IL201690A IL20169009A IL201690A0 IL 201690 A0 IL201690 A0 IL 201690A0 IL 201690 A IL201690 A IL 201690A IL 20169009 A IL20169009 A IL 20169009A IL 201690 A0 IL201690 A0 IL 201690A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- thyroid cancer
- raf inhibitors
- raf
- inhibitors
- Prior art date
Links
- 208000024770 Thyroid neoplasm Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 201000002510 thyroid cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93962507P | 2007-05-23 | 2007-05-23 | |
PCT/US2008/064280 WO2008147782A1 (en) | 2007-05-23 | 2008-05-21 | Raf inhibitors for the treatment of thyroid cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IL201690A0 true IL201690A0 (en) | 2010-05-31 |
Family
ID=39749309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL201690A IL201690A0 (en) | 2007-05-23 | 2009-10-22 | Raf inhibitors for the treatment of thyroid cancer |
Country Status (18)
Country | Link |
---|---|
US (2) | US20100160381A1 (ru) |
EP (1) | EP2150252A1 (ru) |
JP (1) | JP2010528032A (ru) |
KR (1) | KR20100017894A (ru) |
CN (1) | CN101674828A (ru) |
AU (1) | AU2008256922B2 (ru) |
BR (1) | BRPI0811097A2 (ru) |
CA (1) | CA2686787A1 (ru) |
CL (1) | CL2008001492A1 (ru) |
IL (1) | IL201690A0 (ru) |
MA (1) | MA31446B1 (ru) |
MX (1) | MX2009012626A (ru) |
NZ (1) | NZ580592A (ru) |
RU (1) | RU2009147291A (ru) |
TN (1) | TN2009000486A1 (ru) |
TW (1) | TW200914008A (ru) |
WO (1) | WO2008147782A1 (ru) |
ZA (1) | ZA200907250B (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
WO2017136741A1 (en) * | 2016-02-05 | 2017-08-10 | Evol Science LLC | Combinations to treat cancer |
CA3072181A1 (en) * | 2017-08-07 | 2019-02-14 | Evol Science LLC | Combinations to treat cancer |
AU2020206036A1 (en) | 2019-01-11 | 2021-08-05 | Naegis Pharmaceuticals Inc. | Leukotriene synthesis inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE435015T1 (de) * | 2003-10-16 | 2009-07-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
PE20070427A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas |
CN101679372A (zh) * | 2007-03-02 | 2010-03-24 | 诺瓦提斯公司 | Raf激酶抑制剂的固体形式 |
-
2008
- 2008-05-21 RU RU2009147291/15A patent/RU2009147291A/ru not_active Application Discontinuation
- 2008-05-21 JP JP2010509506A patent/JP2010528032A/ja active Pending
- 2008-05-21 NZ NZ580592A patent/NZ580592A/en not_active IP Right Cessation
- 2008-05-21 MX MX2009012626A patent/MX2009012626A/es not_active Application Discontinuation
- 2008-05-21 KR KR1020097026739A patent/KR20100017894A/ko not_active Application Discontinuation
- 2008-05-21 EP EP20080755991 patent/EP2150252A1/en not_active Withdrawn
- 2008-05-21 CA CA002686787A patent/CA2686787A1/en not_active Abandoned
- 2008-05-21 CN CN200880014174A patent/CN101674828A/zh active Pending
- 2008-05-21 US US12/600,720 patent/US20100160381A1/en not_active Abandoned
- 2008-05-21 BR BRPI0811097-2A2A patent/BRPI0811097A2/pt not_active IP Right Cessation
- 2008-05-21 WO PCT/US2008/064280 patent/WO2008147782A1/en active Application Filing
- 2008-05-21 AU AU2008256922A patent/AU2008256922B2/en not_active Ceased
- 2008-05-22 CL CL2008001492A patent/CL2008001492A1/es unknown
- 2008-05-22 TW TW097118933A patent/TW200914008A/zh unknown
-
2009
- 2009-10-16 ZA ZA200907250A patent/ZA200907250B/xx unknown
- 2009-10-22 IL IL201690A patent/IL201690A0/en unknown
- 2009-11-20 TN TNP2009000486A patent/TN2009000486A1/fr unknown
- 2009-12-14 MA MA32420A patent/MA31446B1/fr unknown
-
2012
- 2012-04-26 US US13/457,273 patent/US20120213867A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2009147291A (ru) | 2011-06-27 |
AU2008256922A1 (en) | 2008-12-04 |
KR20100017894A (ko) | 2010-02-16 |
BRPI0811097A2 (pt) | 2014-12-09 |
WO2008147782A1 (en) | 2008-12-04 |
MX2009012626A (es) | 2009-12-07 |
CA2686787A1 (en) | 2008-12-04 |
US20120213867A1 (en) | 2012-08-23 |
ZA200907250B (en) | 2010-07-28 |
NZ580592A (en) | 2012-02-24 |
MA31446B1 (fr) | 2010-06-01 |
JP2010528032A (ja) | 2010-08-19 |
EP2150252A1 (en) | 2010-02-10 |
TN2009000486A1 (en) | 2011-03-31 |
CL2008001492A1 (es) | 2009-02-20 |
CN101674828A (zh) | 2010-03-17 |
TW200914008A (en) | 2009-04-01 |
US20100160381A1 (en) | 2010-06-24 |
AU2008256922B2 (en) | 2011-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2303021T3 (pl) | Związki do leczenia nowotworu | |
EP2318406A4 (en) | THIOSEMICARBAZONHERMAL COMPOUNDS AND CANCER TREATMENT PROCEDURES | |
EP1991230A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
ZA201003123B (en) | Thiazol derivavtives for treating cancer | |
HK1143157A1 (en) | 4-pyridinone compounds and their use for cancer 4- | |
ZA201003425B (en) | 5-cyano-thienopyridines for the treatment of tumors | |
HK1212218A1 (en) | Organoarsenic compounds and methods for the treatment of cancer | |
EP2144887A4 (en) | PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER | |
EP2144888A4 (en) | METHODS OF TREATING CANCER | |
EP2150270A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
HK1151971A1 (en) | Compounds for use in the treatment of cancer | |
IL210066A0 (en) | Novel ortho-aminoanilides for the treatment of cancer | |
EP1986656A4 (en) | WITHACNISTINE COMPOUNDS FOR THE TREATMENT OF CANCER | |
IL201690A0 (en) | Raf inhibitors for the treatment of thyroid cancer | |
EP2451451A4 (en) | METHODS BASED ON HDAC 6 INHIBITOR FOR THE TREATMENT OF CANCER | |
IL226363A0 (en) | Compounds and methods for treating cancer | |
GB0707556D0 (en) | Treatment for cancer | |
HK1209754A1 (en) | Compounds and methods for the treatment of cancer | |
AP2011005893A0 (en) | Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer. | |
EP2214485A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
GB0604114D0 (en) | Combinations for the treatment of cancer | |
GB0712513D0 (en) | Treatment of cancer | |
GB0700493D0 (en) | Cancer treatment | |
GB0723503D0 (en) | Cancer treatment |